Author

W. A. Michaud

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

G. M. Boland· 2 shared A. Mehta· 1 shared A. Shi· 1 shared D. Johnson· 1 shared D. Plana· 1 shared D. T. Frederick· 1 shared G. G. Kasumova· 1 shared I. Chien· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

G. M. Boland

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MicrobiologybioRxivPreprintAug 25, 2020

The SARS-CoV-2 Spike mutation D614G increases entry fitness across a range of ACE2 levels, directly outcompetes the wild type, and is preferentially incorporated into trimers

W. A. Michaud, G. M. Boland, S. A. Rabi

DOI 10.1101/2020.08.25.267500

virusproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintOct 18, 2019

Plasma-derived exosomal analysis and deconvolution enables prediction and tracking of melanoma checkpoint blockade response

A. Shi, G. G. Kasumova, W. A. Michaud…·G. M. Boland

This paper uses plasma-derived exosomal RNA to predict and track melanoma response to immune checkpoint inhibitors by analyzing tumor and immune signatures.

DOI 10.1101/809699

humanbulk RNA-seq

𝕏 PostBluesky